CS2164 exerts an antitumor effect against human Non‐Hodgkin's lymphomas in vitro and in vivo
Sign Up to like & getrecommendations! Published in 2018 at "Experimental Cell Research"
DOI: 10.1016/j.yexcr.2018.05.038
Abstract: Abstract Non‐Hodgkin's lymphomas (NHLs) are a heterogeneous group of lymphoproliferative disorders. Mounting studies have suggested an involvement of angiogenesis signaling in NHLs progression and resistance to treatment. In this study, we investigated the cytotoxicity of… read more here.
Keywords: hodgkin lymphomas; cs2164 exerts; vivo; non hodgkin ... See more keywords
CS2164, a novel multi‐target inhibitor against tumor angiogenesis, mitosis and chronic inflammation with anti‐tumor potency
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Science"
DOI: 10.1111/cas.13141
Abstract: Although inhibitors targeting tumor angiogenic pathway have provided improvement for clinical treatment in patients with various solid tumors, the still very limited anti‐cancer efficacy and acquired drug resistance demand new agents that may offer better… read more here.
Keywords: inhibitor; multi; angiogenesis; chronic inflammation ... See more keywords